期刊文献+

治疗慢性肾病中药计算机网络药理学研究 被引量:12

Computational network pharmacological research of Chinese medicinal plants for chronic disease
原文传递
导出
摘要 药物分子和靶标之间的相互作用是其药理作用的基础.运用分子对接和复杂网络分析技术研究治疗慢性肾病中药所含化学成分和靶标之间的相互作用.结果显示治疗慢性肾病中药所含化学成分-靶标相互作用网络与西药的化学成分-靶标相互作用网络存在较大的差异,这说明中药的作用机制和西药的作用机制不完全相同.研究还发现补益类中药所含化学成分-靶标相互作用网络与攻逐类中药所含化学成分-靶标相互作用网络也存在较大差异,这从复杂网络研究视角阐释了古老的中药分类理论.这种研究方法可以快速筛选出治疗慢性肾病中药中的有效成分群及其关键靶标,为组分中药的研发提供实验数据. The interaction between drug molecules and target proteins is basis of pharmacological action. The pharmacodynamic mechanism of Chinese medicinal plants for chronic kidney disease (CKD) was studied by molecular docking and complex network analysis. It was found that the interaction network of components-proteins of Chinese medicinal plants is different from interaction network of components-proteins of drugs. It showed the mechanism of action of Chinese medicinal plants is different from that of drugs. We also found the interaction network of components-proteins of tonifing herbs is different from interaction network of components-proteins of evil expelling herbs from complex network research approach. It illuminated the ancient theory of classification of Chinese medicinal plants. This computational approach could identify the pivotal components of Chinese medicinal plants and their key target proteins rapidly. The results provided data for development of multi-component Chinese medicine.
出处 《中国科学:化学》 CAS CSCD 北大核心 2010年第8期1085-1090,共6页 SCIENTIA SINICA Chimica
基金 广东省科技计划重大项目(2009A030100006) 广东省自然科学基金(9151063201000050) 广东省中医药局建设中医药强省科研课题(2008334)资助
关键词 慢性肾脏病 中药 分子对接 复杂网络 chronic kidney disease traditional Chinese medicine (TCM) molecular docking complex network
  • 相关文献

参考文献29

  • 1谌贻璞.要认真地重视慢性肾脏病防治[J].中华临床医师杂志(电子版),2009,3(6):7-10. 被引量:8
  • 2黎磊石,刘志红.应用雷公藤治疗肾炎二十五载的体会[J].肾脏病与透析肾移植杂志,2003,12(3):246-247. 被引量:135
  • 3Zhu W, Wang XM, Zhang L, Li XY, Wang BX. Pharmacokinetic of rhein in healthy male volunteers following oral and retention enema administration of rhubarb extract: a single dose study. Am J Chin Med, 2005, 33:839--850.
  • 4Jia J, Zhu F, Ma XH, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov, 2009, 8:111-128.
  • 5Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today, 2007, 12:34-42.
  • 6Hippisley CJ, Coupland C. Effect of combinations of two drugs on all cause in patients with ischaemic heart disease: Nested case-control analysis. Brit Med J, 2005, 330:1059--1063.
  • 7Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Chen SL, Fiedorek FT, Belder R. Additive benefits of pravastain and aspirin to decrease risks of cardiovascular disease. Arch Intern Med, 2003, 164: 40--44.
  • 8The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet, 2009, 373:1341--1351.
  • 9朱伟,阮新民,陈可冀.正确认识循证医学在中医药学中应用的现状[J].中医杂志,2006,47(5):333-335. 被引量:12
  • 10Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen S J, Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-lndigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA, 2008, 105, 4826.

二级参考文献119

共引文献244

同被引文献237

引证文献12

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部